Nicholas D.E. Greene

Dr. Nicholas D.E. Greene

Developmental Biology & Cancer Programme, UCL Great Ormond Street Institute of Child Health, University College London, London, UK
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Cell
Verified
Journal Article
Open access
FCFilipe Cabreiro
Filipe Cabreiro
CACatherine Au
Catherine Au
KLKit-Yi Leung
Kit-Yi Leung
NVNuria Vergara-Irigaray
Nuria Vergara-Irigaray
HCHelena M. Cochemé
Helena M. Cochemé
DGDavid Gems
David Gems
The biguanide drug metformin is widely prescribed to treat type 2 diabetes and metabolic syndrome, but its mode of action remains uncertain. Metformin also increases lifespan in Caenorhabditis elegans cocultured with Escherichia coli. This bacterium exerts complex nutritional and pathogenic effects on its nematode predator/host that impact health and aging. We report that metformin increases lifespan by altering microbial folate and methionine metabolism. Alterations in metformin-induced longevity by mutation of worm methionine synthase (metr-1) and S-adenosylmethionine synthase (sams-1) imply metformin-induced methionine restriction in the host, consistent with action of this drug as a dietary restriction mimetic. Metformin increases or decreases worm lifespan, depending on E. coli strain metformin sensitivity and glucose concentration. In mammals, the intestinal microbiome influences host metabolism, including development of metabolic disease. Thus, metformin-induced alteration of microbial metabolism could contribute to therapeutic efficacy-and also to its side effects, which include folate deficiency and gastrointestinal upset.

8 July 2014 in Annual Review of Neuroscience
Verified
Journal Article
Closed access
NGNicholas D.E. Greene
Nicholas D.E. Greene
ACAndrew Copp
Andrew Copp
Neural tube defects (NTDs), including spina bifida and anencephaly, are severe birth defects of the central nervous system that originate during embryonic development when the neural tube fails to close completely. Human NTDs are multifactorial, with contributions from both genetic and environmental factors. The genetic basis is not yet well understood, but several nongenetic risk factors have been identified as have possibilities for prevention by maternal folic acid supplementation. Mechanisms underlying neural tube closure and NTDs may be informed by experimental models, which have revealed numerous genes whose abnormal function causes NTDs and have provided details of critical cellular and morphological events whose regulation is essential for closure. Such models also provide an opportunity to investigate potential risk factors and to develop novel preventive therapies.

1 October 2003 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
ACAndrew Copp
Andrew Copp
NGNicholas D.E. Greene
Nicholas D.E. Greene
JMJennifer N. Murdoch
Jennifer N. Murdoch

1 August 2013 in The Lancet Neurology
Verified
Journal Article
Closed access
ACAndrew Copp
Andrew Copp
PSPhilip Stanier
Philip Stanier
NGNicholas D.E. Greene
Nicholas D.E. Greene

15 February 2017 in Development
Verified
Journal Article
Open access
PDF file
ENEvanthia Nikolopoulou
Evanthia Nikolopoulou
GGGabriel L. Galea
Gabriel L. Galea
ARAna Rolo
Ana Rolo
NGNicholas D.E. Greene
Nicholas D.E. Greene
ACAndrew Copp
Andrew Copp
Neural tube closure has been studied for many decades, across a range of vertebrates, as a paradigm of embryonic morphogenesis. Neurulation is of particular interest in view of the severe congenital malformations – ‘neural tube defects’ – that result when closure fails. The process of neural tube closure is complex and involves cellular events such as convergent extension, apical constriction and interkinetic nuclear migration, as well as precise molecular control via the non-canonical Wnt/planar cell polarity pathway, Shh/BMP signalling, and the transcription factors Grhl2/3, Pax3, Cdx2 and Zic2. More recently, biomechanical inputs into neural tube morphogenesis have also been identified. Here, we review these cellular, molecular and biomechanical mechanisms involved in neural tube closure, based on studies of various vertebrate species, focusing on the most recent advances in the field.

13 November 2009 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
ACAndrew Copp
Andrew Copp
NGNicholas D.E. Greene
Nicholas D.E. Greene
Congenital defects of neural tube closure (neural tube defects; NTDs) are among the commonest and most severe disorders of the fetus and newborn. Disturbance of any of the sequential events of embryonic neurulation produce NTDs, with the phenotype (eg anencephaly, spina bifida) varying depending on the region of neural tube that remains open. While mutation of > 200 genes is known to cause NTDs in mice, the pattern of occurrence in humans suggests a multifactorial polygenic or oligogenic aetiology. This emphasizes the importance of gene–gene and gene–environment interactions in the origins of these defects. A number of cell biological functions are essential for neural tube closure, with defects of the cytoskeleton, cell cycle and molecular regulation of cell viability prominent among the mouse NTD mutants. Many transcriptional regulators and proteins that affect chromatin structure are also required for neural tube closure, although the downstream molecular pathways regulated by these proteins is unknown. Some key signalling pathways for NTDs have been identified: over‐activation of sonic hedgehog signalling and loss of function in the planar cell polarity (non‐canonical Wnt) pathway are potent causes of NTD, with requirements also for retinoid and inositol signalling. Folic acid supplementation is an effective method for primary prevention of a proportion of NTDs in both humans and mice, although the embryonic mechanism of folate action remains unclear. Folic acid‐resistant cases can be prevented by inositol supplementation in mice, raising the possibility that this could lead to an additional preventive strategy for human NTDs in future. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.